Tax incentives for R&D, quicker FDA approvals needed to stem exodus of U.S. medical device firms, industry studies show. More
-
-
Sponsored By:
-
Sponsored By:
Health
(RSS)
Heed the Red Flags at Amedisys
Congressional scrutiny of home health care specialist Amedisys, along with lowered guidance, are sure-fire signs that investors should proceed with care. More
Lilly Should Survive Patent Loss on Blockbuster Drug Zyprexa
On Oct. 23, Eli Lilly will wave goodbye to the U.S. patent on the best-selling drug in its 135-year history. Here's why investors shouldn't be worried. More
Onyx’s Staying Power Tied to New Cancer Drug Carfilzomib
Onyx needs the financial boost from its multiple myeloma-treating drug to ween it off dependence on an uneasy partnership with Bayer. More
Suit Asks J&J CEO to Return Part of 2010 Pay
J&J CEO Bill Weldon’s gains don’t reflect shareholder pain, some stakeholders say. More
Study Results Boost Analyst’s Forecast for Novartis Drug
An analyst boosts his forecast for Novartis' Afinitor based on its promise as a treatment for breast cancer. More
FDA’s Easing on Obesity Drugs Could Fatten Investor Wallets
Vivus and Orexigen's diet-pill hopes are resurrected as the FDA relaxes its stance against obesity treatments. More
